As of 6 Nov 2026, Bafna Pharmaceuticals trades at 138.1× trailing earnings, above the industry P/E of 28.7×. Its ROCE of 12% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 9.3% a year over 3 years while net profit fell 0.7%. Debt is 0.39× equity. It is a small-cap company with a market cap of ₹1,075 Cr, ranked 68th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 183% over the past year.
- ₹456.50
- ₹456.50
- ₹454.40
- ₹447.55
- 10.2K
Health check
- ReturnsAhead
+182.7% over a year, better than 7 of 7 peers.
- Price tagPricier
P/E 138.1 vs industry 28.7.
- GrowthSlow
Sales +9.3%, profit −0.7% a year over 3 years.
- ProfitabilityWeak
ROCE 12.2% vs peer median 17.9%.
- Balance sheetFair
Debt 0.39× equity, interest covered 4.1×, Piotroski 6 of 9.
- Red flags3 to check
Quarterly profit down 97.8% on a year ago.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹1,075 Cr
- Small cap
- P/E
- 138.1
- Industry 28.7
- Price to book
- 11.20
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 12.3%
- Peers 14.7%
- ROCE
- 12.2%
- Peers 17.9%
- Debt to equity
- 0.39
- Debt ₹37 Cr
- EPS (TTM)
- ₹3.29
- Face value ₹10
- OPM (TTM)
- 8.2%
- Net margin 5.5%
- Sales growth
- −23.2%
- Latest quarter vs a year ago
- Profit growth
- −97.8%
- Latest quarter vs a year ago
- Price to sales
- 7.54
- EV/EBITDA 100.7
Strengths and risks
Strengths
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Quarterly profit down 97.8% on a year ago.
- Quarterly sales down 23.2% on a year ago.
- P/E of 138.1 against an industry P/E of 28.7.
About Bafna Pharmaceuticals
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company offers its products in various dosage forms, including tablets, capsules, and solid orals. It provides various products for cardiovascular and hypertension, potent oncology, anti-infectives, central nervous system, and diabetic related diseases, as well as provision of contract research and manufacturing services. It also exports its products to…
- Headquarters
- Chennai
- Employees
- 339
- Sector
- Healthcare
- ISIN
- INE878I01022
- Website
- bafnapharma.com
Price range
- Avg volume (3M)
- 7.3K
- 1-year return
- plus 182.7%
- From 52-week high
- minus 5.3%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| BAFNAPHBafna Pharmaceuticals | 454.50 | plus 1.55% | 1,075 | 138.1 | 11.20 | 12.2% | 12.3% | 8.2% | 9.3% | −0.7% | 0.00% | plus 182.7% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 34.6 | 35.5 | 38.3 | 42.2 | 26.6 | |
| 29.6 | 31.2 | 35.2 | 38.7 | 25.7 | |
| 5.1 | 4.3 | 3 | 3.5 | 0.9 | |
| 14.6% | 12.1% | 8.0% | 8.4% | 3.3% | |
| 0.6 | 1.2 | 1.2 | 1.8 | 1.9 | |
| 0.9 | 0.9 | 0.9 | 1 | 0.9 | |
| 1.4 | 1.5 | 1.6 | 1.7 | 1.8 | |
| 3.4 | 3.1 | 1.8 | 2.6 | 0.1 | |
| – | – | – | −4.9% | – | |
| 3.4 | 3.1 | 1.8 | 2.7 | 0.1 | |
| 1.43 | 1.32 | 0.78 | 1.16 | 0.03 |
Profit & loss
- Sales CAGR 3Y
- +9.3%
- Profit CAGR 3Y
- −0.7%
- EPS CAGR 3Y
- −0.7%
- ROE
- 12.3%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 115 | 152 | 146 | 151 | |
| – | +32.2% | minus 4.3% | +3.3% | |
| 97.9 | 140 | 134 | 134 | |
| 17.4 | 12.4 | 11.9 | 16.6 | |
| 15.1% | 8.1% | 8.1% | 11.0% | |
| 1.3 | 1.9 | 1.8 | 3.9 | |
| 1.8 | 1.9 | 2.6 | 3.5 | |
| 5.3 | 5 | 4.9 | 6.1 | |
| 0 | −0 | −2 | 0 | |
| 11.6 | 7.3 | 4.2 | 11 | |
| 2.4% | – | – | −1.2% | |
| 11.3 | 7.3 | 4.2 | 11.1 | |
| – | minus 35.2% | minus 43.5% | +167.3% | |
| 4.79 | 3.11 | 1.76 | 4.69 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 23.7 | 23.7 | 23.7 | 23.7 | |
| 49.8 | 57.2 | 61.2 | 72.5 | |
| 22.9 | 24.4 | 28.2 | 37.4 | |
| 33.2 | 42.5 | 40.1 | 41.9 | |
| 130 | 148 | 153 | 176 | |
| 40.2 | 50.7 | 66.1 | 84.9 | |
| – | 10.5 | 7.3 | 3.1 | |
| – | 0.7 | 0 | 0 | |
| 7.8 | 1.4 | 3.4 | 2 | |
| 81.5 | 84.4 | 76.2 | 85.4 | |
| 130 | 148 | 153 | 176 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 5 | 9.5 | 22.1 | 15.4 | |
| −7.5 | −15.1 | −21.2 | −22.4 | |
| 10.2 | −0.8 | 1.1 | 5.6 | |
| 7.6 | −6.4 | 2 | −1.4 | |
| −8.2 | −15.8 | −21.9 | −24.9 | |
| −3.3 | −6.4 | 0.3 | −9.5 |
Shareholding pattern
- Promoters75.00%
- Public25.00%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 75.00% | 25.00% | 0.00 | |
| 30 Jun 2026 | 75.00% | 25.00% | 0.00 | |
| 31 Mar 2026 | 75.00% | 25.00% | 0.00 | |
| 31 Dec 2025 | 75.00% | 25.00% | 0.00 | |
| 30 Sep 2025 | 75.00% | 25.00% | – |
Major shareholders
Filings & events
News
No recent news coverage found.